NASDAQ:AXSM

Axsome Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AXSM

*Your capital is at risk

$233.49

+11.33 (+5.10%)

At Close: Jun 03, 2026

Axsome Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -79.16. In total, the insiders bought 1.56M and sold 667.52K AXSM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-79.16
● Buy	1.56M shares
● Sell	667.52K shares
71% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Apr 21, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -79.16. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 26, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Jacobson Mark L. Chief Operating Officer	C-Suite Officer	35 378 Value: $100.8K
Feb 23, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Coleman Mark Director	Director	6 250 Value: $30.9K
Feb 23, 2026 Buy	Common Stock M-Exempt	Coleman Mark Director	Director	6 250 Value: $30.9K
Feb 20, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Coleman Mark Director	Director	12 485 Value: $61.8K
Feb 20, 2026 Buy	Common Stock M-Exempt	Coleman Mark Director	Director	12 485 Value: $61.8K
Feb 10, 2026 Buy	Common Stock M-Exempt	Coleman Mark Director	Director	5 193 Value: $41.6K
Feb 10, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Coleman Mark Director	Director	5 193 Value: $41.6K
Feb 02, 2026 Buy	Common Stock M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	32 410 Value: $259.9K
Feb 02, 2026 Sell	Common Stock S-Sale	Tabuteau Herriot Chief Executive Officer	CEO / President	32 410 Value: $6.02M
Feb 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	32 410 Value: $6.02M
Jan 22, 2026 Buy	Common Stock M-Exempt	Pizzie Nick Chief Financial Officer	C-Suite Officer	12 000 Value: $42.0K
Jan 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Pizzie Nick Chief Financial Officer	C-Suite Officer	12 000 Value: $42.0K
Jan 22, 2026 Sell	Common Stock S-Sale	Pizzie Nick Chief Financial Officer	C-Suite Officer	12 000 Value: $2.26M
Jan 21, 2026 Sell	Common Stock S-Sale	Maizel Ari Chief Commercial Officer	Officer	7 500 Value: $1.38M
Jan 21, 2026 Buy	Common Stock M-Exempt	Maizel Ari Chief Commercial Officer	Officer	7 500 Value: $530.5K
Jan 21, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Maizel Ari Chief Commercial Officer	Officer	7 500 Value: $530.5K
Jan 07, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	31 261 Value: $5.33M
Jan 07, 2026 Buy	Common Stock M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	31 261 Value: $250.7K
Jan 07, 2026 Sell	Common Stock S-Sale	Tabuteau Herriot Chief Executive Officer	CEO / President	31 261 Value: $5.33M
Jan 06, 2026 Sell	Common Stock S-Sale	Tabuteau Herriot Chief Executive Officer	CEO / President	29 450 Value: $5.08M
Jan 06, 2026 Buy	Common Stock M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	29 450 Value: $236.2K
Jan 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	29 450 Value: $5.08M
Jan 05, 2026 Buy	Common Stock M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	78 703 Value: $631.2K
Jan 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Tabuteau Herriot Chief Executive Officer	CEO / President	78 703 Value: $13.5M
Jan 05, 2026 Sell	Common Stock S-Sale	Tabuteau Herriot Chief Executive Officer	CEO / President	78 703 Value: $13.5M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AXSOME THERAPEUTICS

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial ...

Read Full Profile Here